谷氨酰胺在危重病患者中的应用

目的探讨危重病患者中早期经静脉应用谷氨酰胺（glutamine，Gl）的临床价值。方法42例患者随机分成两组（对照组和Gln组），Gln组进行Gln治疗（100mL／d，共7d）。治疗前后检测患者体质量、白蛋白、谷胱甘肽（GSH）、握力的变化和肠功能不全的发生率。结果体质量两组治疗前后比较差异无显著性（P〉0．05）。白蛋白、握力和GSH Gl治疗后非常显著高于治疗前（P〈0．01）；白蛋白对照组治疗后较治疗前显著增高（P〈0．05），但握力和GSH治疗前后均无显著变化（P〉0.05）；肠功能不全的发生率Gln组为4．8％，显著低于对照组（28．6％，P〈0．05）。结论在危重病患者疾病早期通过静脉途径外源性地补充Gln，有效改善了患者的营养状况；使患者血浆中的GSH水平增高，加强了机体的抗氧化能力；减少了患者肠功能不全的发生率。     

含谷氨酰胺双肽肠外营养在门腔分流术后应用的临床研究

目的　探讨门腔分流术后病人给予含丙氨酰 谷氨酰胺双肽 (Ala GLN)肠外营养 (PN)的安全性 ;观察其营养支持的效果 ,及对肠道通透性的影响。方法　 16例病人随机分为两组。对照组(n =7)接受不含GLN的PN ;实验组 (n =9)接受含Ala GLN双肽的PN。两组自术后第 1天起给予等氮、等热量的PN共 7d ,于PN前后分别测定血清前白蛋白、氮平衡变化、血清GLN浓度、血氨、尿乳果糖 /甘露醇排泄率比值 (L/Mratio)、生化和临床指标的变化。结果　对照组术后血清GLN水平比术前显著降低 ,术后实验组GLN水平 (5 77± 4 2 ) μmol/L显著 (P =0 0 0 9)高于对照组术后水平 (499± 6 1)μmol/L ;两组术前的L/M比率均明显高于国人正常水平 ,术后对照组L/M水平 (0 0 95± 0 0 34)显著 (P=0 0 4 5 )高于实验组 (0 0 6 4± 0 0 2 3) ;两组累积氮平衡无显著性差异 ,但实验组第 5～ 7天期间氮平衡要明显优于对照组 ,实验组第 5天氮平衡 (- 15 3± 4 6 9)mg·kg-1·d-1显著 (P =0 0 4 3)好于对照组 (-92 7± 90 5 )mg·kg-1·d-1;对照组术后血清前白蛋白水平较术前显著下降 ,实验组术后血清前白蛋白水平 (0 2 6 9± 0 0 37)g/L显著 (P =0 0 0 1)高于对照组 (0 199± 0 0 2 7)g/L ;两组术后血氨水平相比无统计学意义 ;生     

谷氨酰胺和生长激素对短肠综合征患者肠道代偿作用

目的探讨谷氨酰胺和生长激素对短肠综合征(SBS)患者的肠道代偿作用。方法26例短肠综合征患者残余小肠长度为0～100(中位数42.5)cm,手术后接受肠外营养(PN)支持3-52个月,联合应用生长激素(GH)(0.10±0.06)mg·kg-1·d-1和谷氨酰胺(GLN)(0.30±0.17)g·kg-1·d-1进行肠道促代偿治疗。结果26例接受GH加GLN治疗的SBS患者,其中9例(34.6%)治疗后近期内完全摆脱PN;8例(30.8%)经治疗后明显减少了PN用量,从每周需要PN(6.0±1.0)d下降至(4.2±1.0)d,每周PN需要量从(13.6±5.2)L降至(8.2±3.3)L;9例(34.6%)在治疗后仍依赖PN维持。结论经过合适的营养支持和肠道促代偿治疗,大多数短肠综合征患者残留肠道能充分代偿,完全摆脱PN或减少PN用量,长期健康生存。     

口服谷氨酰胺颗粒对烧创伤患者的疗效及安全性分析

目的观察口服谷氨酰胺(Gln)颗粒对烧(创)伤及大手术患者的疗效及可能发生的不良反应.方法采用随机双盲、安慰剂对照法,将受试患者分为Gln组和对照组,每组60例,两组患者采用等氮、等热量的营养支持.Gln组口服或管饲Gln 0.5 g·kg-1·d-1,对照组使用同等剂量的安慰剂甘氨酸,疗程均为7 d.比较用药前后两组患者肠黏膜屏障功能、蛋白代谢、免疫功能、肝和肾功能的变化及不良反应等. 结果伤后两组患者血浆Gln浓度明显低于正常值,而血浆二胺氧化酶(DAO)活性、内毒素含量、肠黏膜通透性[尿乳果糖/甘露醇(L/M)]及尿氮排量均明显增高;但Gln组用药7 d后血浆Gln浓度与用药前比较增加38.04%(P＜0.01).Gln组血浆前白蛋白、转铁蛋白及白细胞介素2(IL-2)含量均显著高于对照组(P＜0.01),升幅分别为21.19%、51.11%、57.54%.血浆DAO活性、L/M比值、内毒素含量及尿氮排量明显低于对照组,降幅分别为47.26%、52.18%、22.22%、27.78%(P＜0.05或0.01).两组患者的血浆总蛋白、白蛋白、血尿常规及肝、肾功能在用约前后变化不明显(P＞0.05).用药后有少数患者出现轻微不良反应如恶心、腹泻和便秘等,2～3 d后自行缓解,两组间比较,差异无显著性意义(P＞0.05).结论口服Gln能显著提高患者血浆Gln浓度,明显减轻伤后肠黏膜受损程度,并能促进机体蛋白合成,降低蛋白分解,提高机体免疫功能,且临床应用无明显不良反应.     

Reversible shifts in the Ca2+-dependent release of aspartate and glutamate from hippocampal slices with changing glucose concentrations

It is known that low glucose concentrations increase the aspartate and decrease the glutamate content of brain tissue both in vivo and in vitro. To see whether these changes occur in the transmitter compartment or not, the release of aspartate and glutamate evoked by electrical-field stimulation or by high K+ was followed in slices of rat hippocampus superfused with 5 or 0.2 mM glucose. Superfusion with 0.2 mM glucose increased the evoked release of aspartate about ten times and that of glutamate about threefold. This shift in the ratio of aspartate to glutamate released was accompanied by a similar increase in the relative amount of aspartate contained in the slices. The high evoked release of aspartate and glutamate was well maintained, provided 0.5 mM glutamine was added to the medium. Changing the concentration of glucose after the first period of stimulation rapidly altered the relative amounts of aspartate and glutamate released but not the enhanced release of glutamate. The large evoked release of both aspartate and glutamate in 0.2 mM glucose was almost entirely Ca2+-dependent. The relative amounts of aspartate and glutamate released by 50 mM K+ also changed when the glucose concentration was reduced. Results suggest two effects of low glucose concentrations: an increase in the overflow of synaptically released glutamate due to a decreased uptake and an increase in the proportion of aspartate to glutamate formed and released from the transmitter pool. These observations are consistent with the interpretation that these two transmitters can be released in different proportions from the same terminals.     

谷氨酰胺诱导热休克蛋白在感染性休克中的作用

热休克蛋白(heatshockproteins,HSPs)为一组高度保守的蛋白质,因其独特的生物学特性及功能,在生物体内广泛参与了多种复杂的功能活动,人们将其生物活性比喻为“瑞士军刀”[1]。已有研究证明HSPs对感染性休克动物具有保护作用,但是诱导热休克蛋白产生的因素多数对机体有害,体内外实验研究发现Gln能诱导动物的热休克反应,特异性增强起主要保护作用的HSP72和HSP27的表达,从而改善感染性休克动物的生存率。本文对应用Gln诱导体内HSPs表达,从而提高机体对感染性休克的防御作用及可能机制作一综述。1谷氨酰胺对热休克蛋白表达的影响Gln是…     

Glutamine and Other Amino Acid Losses During Continuous Venovenous Hemodiafiltration

Abstract: Serum amino grams and daily losses of glutamine (Gin) and other amino acids (AAs) into diafiltrate were measured during the first 5 days of continuous venovenous hemodiafiltration (CVVHDF) in 6 ICU patients with acute renal failure (ARF). Four patients had ARF as a part of multiple organ failure (MOF) of septic origin, and 2 patients had isolated ARF because of primary renal disease. During the study, all the patients received defined total parenteral nutrition (TPN). The mean daily AA losses into dialysate were relatively low (0.61 ± 0.1 g N ) and reached 4.5% of the daily AA substitution. Gln represented 32.7 ± 5.9% of the total AA losses (0.19 ± 0.04 g N ). Serum levels of Gin (p = 0.002) and of most other AAs were significantly lower in the patients than in the control subjects (AA analysis in 16 healthy volunteers). Phenylalanine (Phe) was the only AA that was increased significantly (p < 0.01) in the patients. The mean patient serum concentrations of Phe and tyrosine were significantly higher (p < 0.03) than the correspondent concentrations in dialysate, but the lysine concentration was higher in dialysate (p < 0.03). The serum and dialysate concentrations of other AAs did not differ. Gin in serum decreased significantly (p < 0.03) on the second day of CVVHDF but returned to the baseline levels subsequently. Serum concentrations of Phe increased on the second day of CVVHDF (p < 0.05). Serum concentrations of other AAs remained stable during the whole study. We conclude that Gin losses into dialysate during CVVHDF are relatively low, but CVVHDF itself may induce changes in Gin metabolism and distribution that are reflected by a decrease of serum Gin levels at the institution of this treatment. Therefore, the need for Gin supplementation in ICU patients is even greater in the first days of CVVHDF.     

选择性消化道去污联合谷氨酰胺预防兔背驮式肝移植肠道细菌易位

目的观察选择性消化道去污(SDD)联合谷氨酰胺(Gln)对兔原位背驮式肝移植肠道细菌易位及术后肺部感染的预防作用。方法建立兔原位背驮式肝移植模型30例,受体兔被随机均分为SDD组、SDD Gln组及对照组。SDD组给予含妥布霉素、多黏菌素E及制霉菌素的乳剂处理;SDD Gln组在SDD的基础上加以Gln;对照组仅建立移植模型。各组分时段抽取门静脉血,获取回肠组织标本及术后肺组织标本,观察回肠组织病理变化、门静脉血细菌易位及术后肺部感染情况。结果门静脉阻断15、30、45min及术后30h SDD Gln组回肠壁毛细血管混合切面面积均小于对照组(P<0.05,P<0.01)和SDD组(P<0.05)。门静脉阻断前SDD Gln组回肠绒毛长度较对照组(P<0.05)和SDD组(P<0.05)长,在门静脉阻断45min时段对照组超过SDD Gln组(P<0.05)和SDD组(P<0.05),术后又回返至术前状态(P<0.05,P<0.01)。门静脉阻断45min和术后30h时段SDD Gln组及SDD组门静脉血细菌培养阳性者少于对照组(P<0.05,P<0.01)。SDD Gln组及SDD组术后肺部感染者也少于对照组(P<0.05,P<0.01)。结论Gln对肠黏膜上皮细胞具有较强的营养作用,与SDD联用可以有效地降低门静脉阻断期间及术后肠道细菌易位及术后肺部感染的发生。     

谷氨酰胺对肝门阻断后肠道损伤的影响及其意义

目的：探讨谷氨酰胺（Gln）对肝门阻断后肠道损伤的影响及其意义.方法：将雄性Wistar大鼠,随机分为三组：假手术组（A组）、对照组（B组）和实验组（C组）.采用Pringle法进行肝门阻断,持续35min,在肝门阻断前C组大鼠腹腔注射Gln.分别于肝门阻断前及再灌注后2、4、24 h,每组各选取10只大鼠,测定肠道组织谷胱甘肽（GSH）、超氧化物歧化酶（SOD）、丙二醛（MDA）的水平,检测血清TNF-α水平以及门静脉血浆内毒素水平.结果：与A组相比,再灌注后B组肠组织中MDA水平增高（P＜0.05）,而GSH及SOD水平下降（P＜0.05）,TNF-α及内毒素水平明显增高（P＜0.05）.再灌注后2h及4h,C组肠道GSH水平均明显高于B组（P＜0.05）.与B组相比,再灌注后C组肠道组织SOD活性明显增高,而MDA水平明显降低（P＜0.05）;血清TNF-α及内毒素水平均明显降低（P＜0.05）.结论：肝门阻断可以造成肠道屏障的破坏;而Gln对肠道屏障具有保护作用,并将减少内毒素易位、炎性因子的释放.     

Isolation of a DNA fragment which complements glutamine synthetase deficient strains ofS. pombe

Summary From a gene bank ofS. pombe DNA, a 5.6 kb clone was isolated which complemented mutants defective in glutamine synthetase (GS) activity. Sub-cloning fragments of this 5.6 kb clone showed that the complementing activity was localised in a 1.6 kb HindIII-Aval fragment and a partial DNA sequence revealed an open reading frame preceded by TATA sequences and a TGACTA sequence. Plasmid constructs carrying up to 3.4 kb of DNA used to transformgln ⁻ strains gave transformants which showed a wide range of GS activity, in some cases 100 times the wild-type level. These constructs identify DNA sequences lying downstream from the putative coding sequence which have effects on the total amount of enzyme activity, but do not affect the control imposed by the nitrogen source on which the cells are grown.